Soriot Stands By His Post-Pfizer Sales Pledge For AstraZeneca
Executive Summary
Pascal Soriot stands by the ambitious growth target he set for AstraZeneca in his defense against Pfizer's 2014 bid for the company. Any shortfall in the target of $45bn by 2023 will reflect the weakening of the dollar rather than product challenges for the UK company, the bullish CEO told Scrip one day after the company delivered disappointing Phase III data that slashed around 15% from its share price.
You may also be interested in...
Pharma Q3 Results Preview: Pfizer, Allergan, Sanofi, Teva & AstraZeneca
Pfizer’s CEO will likely shed more light on the company’s on-off-on attitude towards its consumer health business, while Allergan will certainly have a lot of explaining to do regarding its Restasis patent protection strategy. Sanofi, Teva and AstraZeneca are also scheduled to report Q3 results in the coming days. Scrip outlines the key issues to watch for.
Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel
Teva investors have moved beyond restless to the point of jumping ship as the company's generic drug business continues to underperform, with little guidance on plans for a turnaround.
Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel
Teva investors have moved beyond restless to the point of jumping ship as the company's generic drug business continues to underperform, with little guidance on plans for a turnaround.